Three-Year Outcome of VBX Stent Graft Used as a Bridging Stent in Endovascular Repair of Post-Dissection Thorachoabdominal Aortic Aneurysm
Journal of Cardiovascular Development and Disease · 06.07.2026 · 13 (7) · 311
DOI: 10.3390/jcdd13070311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 06.07.2026. Verfasst von Frida Jonsdottir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Rigshospitalet, 2100 Copenhagen, Denmark. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Post-dissection thoracoabdominal aortic aneurysm (PD-TAAA) is a late sequela of chronic aortic dissection. Complex endovascular aneurysm repair (EVAR), including fenestrated and branched techniques (F/B-EVAR), enables aneurysm exclusion while preserving visceral perfusion; however, bridging stents are not specifically designed for PD-TAAA and are frequently used off-label. Evidence on bridging stent performance is largely derived from degenerative aneurysm cohorts, and PD-TAAA-specific data remain limited. This study evaluated outcomes of the VBX Stent Graft when used as a bridging stent during F/B-EVAR for PD-TAAA. This retrospective analysis included patients with PD-TAAA from the EMBRACE registry (ClinicalTrials.gov: NCT05143138), a multicenter, single-arm registry with retrospective and prospective components, with all outcomes core-laboratory-adjudicated. Procedural, early (thirty-day), and midterm outcomes at one and three years were assessed. The primary endpoints were all-cause mortality and freedom from target vessel instability, defined as loss of durable target vessel reconstruction. Twenty-one patients (mean age 61.5 years; range, 28–77 years) underwent F/B-EVAR with at least one VBX Stent Graft. In total, 82 visceral arteries were treated, of which 51 were bridged with a VBX Stent Graft. Technical success was 100%. Two serious adverse events occurred perioperatively, one requiring reintervention, with no thirty-day mortality or major adverse events. Freedom from all-cause mortality was 95.2% at one year and 90.5% at three years, with two deaths during follow-up. Freedom from target vessel instability at the patient level was 85.7% at both one and three years (95% CI, 62.0–95.2%). VBX Stent Grafts used as bridging stents during F/B-EVAR for PD-TAAA demonstrated high technical success, low early morbidity and mortality, and acceptable mid-term survival and target vessel stability, supporting their use in this challenging anatomical setting within the limitations of a small PD-TAAA cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular Surgery, Rigshospitalet, 2100 Copenhagen, Denmark.
- Department of Clinical and Experimental Sciences (DSCS), University and ASST Spedali Civil Hospital of Brescia, 25123 Brescia, Italy.
ORCID-Profile: Frida Jonsdottir, Luca Bertoglio
Zitieren
APA
Jonsdottir, F., Bertoglio, L., Resch, T., & EMBRACE Investigators (2026). Three-Year Outcome of VBX Stent Graft Used as a Bridging Stent in Endovascular Repair of Post-Dissection Thorachoabdominal Aortic Aneurysm. Journal of Cardiovascular Development and Disease, 13(7), 311. https://doi.org/10.3390/jcdd13070311
Vancouver
Jonsdottir F, Bertoglio L, Resch T, EMBRACE Investigators. Three-Year Outcome of VBX Stent Graft Used as a Bridging Stent in Endovascular Repair of Post-Dissection Thorachoabdominal Aortic Aneurysm. Journal of Cardiovascular Development and Disease. 2026;13(7):311. doi:10.3390/jcdd13070311
BibTeX
@article{Jonsdottir2026,
author = {Jonsdottir, Frida and Bertoglio, Luca and Resch, Timothy and EMBRACE Investigators, EMBRACE Investigators},
title = {Three-Year Outcome of VBX Stent Graft Used as a Bridging Stent in Endovascular Repair of Post-Dissection Thorachoabdominal Aortic Aneurysm},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {7},
pages = {311},
doi = {10.3390/jcdd13070311}
}
EUVIMED